Cargando…
Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines
PURPOSE: Gut microbiota dysbiosis, a core pathophysiology of irritable bowel syndrome (IBS), is closely related to immunological and metabolic functions. Gut microbiota-based therapeutics have been recently explored in several studies. Bifico is a probiotic cocktail widely used in gastrointestinal d...
Autores principales: | Zhou, Yanlin, Zhang, Fan, Mao, Liqi, Feng, Tongfei, Wang, Kaijie, Xu, Maosheng, Lv, Bin, Wang, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899748/ https://www.ncbi.nlm.nih.gov/pubmed/35918555 http://dx.doi.org/10.1007/s00394-022-02958-0 |
Ejemplares similares
-
The prophylactic effects of BIFICO on the antibiotic-induced gut dysbiosis and gut microbiota
por: Wu, Jiannong, et al.
Publicado: (2020) -
Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome
por: Wollny, Tomasz, et al.
Publicado: (2021) -
Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives
por: FJELDHEIM DALE, Hanna, et al.
Publicado: (2020) -
Pretreatment with probiotic Bifico ameliorates colitis‐associated cancer in mice: Transcriptome and gut flora profiling
por: Song, Huan, et al.
Publicado: (2018) -
Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome
por: Wang, Zhe, et al.
Publicado: (2019)